文献速递其他结缔组织病自身炎症与 IgG4 相关病

白塞病风险变异 HLA-B51/ERAP1-Hap10 改变人类 CD8 T 细胞免疫

Behçet's disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunity.
PubMed 文献 · Ann Rheum Dis · 2022-08-03

研究纳入 26 例未治疗土耳其白塞病患者与 22 名健康供者进行基因分型与免疫表型分析,并用 CRISPR-Cas9 构建 ERAP1 敲除的 HLA-B*51 阳性 LCL 分析肽组与 CD8 T 细胞免疫原性。结果显示 ERAP1-Hap10 携带者与非携带者在 HLA-B*51 背景下的 CD8 T 细胞亚群频率存在偏移,ERAP1 敲除细胞肽组中出现超过 9 个氨基酸的较长肽段,且刺激同种反应性 CD8 T 细胞的能力与野生型对照细胞存在显著差异。作者认为低活性 ERAP1 通过 HLA I 类肽组中修剪不足的肽段改变对 CD8 T 细胞的免疫原性。

要点

  • ERAP1-Hap10 等位基因频率与既往研究相似。
  • 在 HLA-B*51 背景下,ERAP1-Hap10 携带者与非携带者的抗原经历与初始 CD8 T 细胞群体间存在频率偏移。
  • ERAP1 敲除细胞肽组出现超过 9 个氨基酸的较长肽段,刺激同种反应性 CD8 T 细胞能力与野生型对照细胞存在显著差异。

核心结论

  • 低活性 ERAP1 通过 HLA I 类肽组中修剪不足的肽段改变对 CD8 T 细胞的免疫原性。
  • 受影响携带者中初始与效应 CD8 T 细胞的偏移为 ERAP1-Hap10/HLA-B*51 的生物学相关性提供细胞水平证据,并指向 HLA-B51 限制性过程。
  • 作者认为变异 ERAP1-Hap10 通过产生 HLA-B51 限制性肽段参与白塞病发病,导致后续 CD8 T 细胞应答的免疫优势发生改变。

研究设计与样本

  • 对 26 例未治疗土耳其白塞病患者与 22 名健康供者进行基因分型与免疫表型分析。
  • 用 CRISPR-Cas9 从 HLA-B*51 阳性 LCL 构建 ERAP1 敲除细胞。
  • 分析 HLA I 类结合肽组以比较肽段长度差异,并在 CD8 T 细胞共培养系统中评估基因组编辑细胞的免疫原性。

主要发现

  • ERAP1-Hap10 等位基因频率与既往研究相似。
  • 在 HLA-B*51 背景下,ERAP1-Hap10 携带者与非携带者的抗原经历与初始 CD8 T 细胞群体间存在频率偏移。
  • ERAP1 敲除细胞肽组出现超过 9 个氨基酸的较长肽段。
  • ERAP1 敲除细胞刺激同种反应性 CD8 T 细胞的能力与野生型对照细胞存在显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The endoplasmic reticulum aminopeptidase (ERAP1) haplotype Hap10 encodes for a variant allotype of the endoplasmic reticulum (ER)-resident peptide-trimming aminopeptidase ERAP1 with low enzymatic activity. This haplotype recessively confers the highest risk for Behçet's diseases (BD) currently known, but only in carriers of HLA-B*51, the classical risk factor for the disease. The mechanistic implications and biological consequences of this epistatic relationship are unknown. Here, we aimed to determine its biological relevance and functional impact. METHODS: We genotyped and immune phenotyped a cohort of 26 untreated Turkish BD subjects and 22 healthy donors, generated CRISPR-Cas9 ERAP1 KOs from HLA-B*51 + LCL, analysed the HLA class I-bound peptidome for peptide length differences and assessed immunogenicity of genome-edited cells in CD8 T cell co-culture systems. RESULTS: Allele frequencies of ERAP1-Hap10 were similar to previous studies. There were frequency shifts between antigen-experienced and naïve CD8 T cell populations of carriers and non-carriers of ERAP1-Hap10 in an HLA-B*51 background. ERAP1 KO cells showed peptidomes with longer peptides above 9mer and significant differences in their ability to stimulate alloreactive CD8 T cells compared with wild-type control cells. CONCLUSIONS: We demonstrate that hypoactive ERAP1 changes immunogenicity to CD8 T cells, mediated by an HLA class I peptidome with undertrimmed peptides. Naïve/effector CD8 T cell shifts in affected carriers provide evidence of the biological relevance of ERAP1-Hap10/HLA-B*51 at the cellular level and point to an HLA-B51-restricted process. Our findings suggest that variant ERAP1-Hap10 partakes in BD pathogenesis by generating HLA-B51-restricted peptides, causing a change in immunodominance of the ensuing CD8 T cell response.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Cavers A, Kugler MC, Ozguler Y, et al. Behçet's disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunity. Ann Rheum Dis. 2022. PMID: 35922122. doi:10.1136/ard-2022-222277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。